scispace - formally typeset
D

Dennis Joseph Mcnamara

Researcher at Parke-Davis

Publications -  49
Citations -  2404

Dennis Joseph Mcnamara is an academic researcher from Parke-Davis. The author has contributed to research in topics: Peptide & Autophosphorylation. The author has an hindex of 23, co-authored 49 publications receiving 2356 citations. Previous affiliations of Dennis Joseph Mcnamara include Pfizer & University of Michigan.

Papers
More filters
Patent

Irreversible inhibitors of tyrosine kinases

TL;DR: In this article, a method for treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
Journal ArticleDOI

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

TL;DR: A direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.
Journal ArticleDOI

Substrate specificity of the protein tyrosine phosphatases.

TL;DR: The results demonstrate that chemical features in the primary structure surrounding the dephosphorylation site contribute to PTPase substrate specificity and suggest that phosphate dianion is favored for substrate binding.
Journal ArticleDOI

Protein tyrosine phosphatase substrate specificity: size and phosphotyrosine positioning requirements in peptide substrates

TL;DR: It is demonstrated that the thiophosphoryl analog in which one of the phosphate oxygens is replaced by sulfur can be hydrolyzed by PTPases, whereas the phosphonomethylphenylalanine analog is a competitive and nonhydrolyzable inhibitor.
Journal ArticleDOI

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

TL;DR: It is reported that the introduction of a methyl substituent at the C-5 position of the pyrido[2,3-d]pyrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases.